IL109749A - Rectal Pharmaceutical Preparations Containing 1, 2, 3, 9 - Tetrahydro - 9 - Methyl -3 -]) 2 - Methyl - H1 - Imidazole - 1 - Il (- Methyl - - Google Patents
Rectal Pharmaceutical Preparations Containing 1, 2, 3, 9 - Tetrahydro - 9 - Methyl -3 -]) 2 - Methyl - H1 - Imidazole - 1 - Il (- Methyl -Info
- Publication number
- IL109749A IL109749A IL10974994A IL10974994A IL109749A IL 109749 A IL109749 A IL 109749A IL 10974994 A IL10974994 A IL 10974994A IL 10974994 A IL10974994 A IL 10974994A IL 109749 A IL109749 A IL 109749A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- pharmaceutical composition
- active ingredient
- imidazol
- tetrahydro
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 3
- -1 2-methyl-1h-imidazol-1-yl Chemical group 0.000 title description 3
- 239000004480 active ingredient Substances 0.000 claims description 19
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 17
- 239000000829 suppository Substances 0.000 claims description 17
- 239000012458 free base Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 10
- 206010047700 Vomiting Diseases 0.000 claims description 7
- 229940116364 hard fat Drugs 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 102000035037 5-HT3 receptors Human genes 0.000 claims description 5
- 108091005477 5-HT3 receptors Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 239000007909 solid dosage form Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000003925 fat Substances 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940116338 glyceryl ricinoleate Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- VRSLTNZJOUZKLX-UHFFFAOYSA-N Ondansetron hydrochloride Chemical compound O.O.Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 VRSLTNZJOUZKLX-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940100681 rectal cream Drugs 0.000 description 1
- 229940041666 rectal gel Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939310756A GB9310756D0 (en) | 1993-05-25 | 1993-05-25 | Compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL109749A0 IL109749A0 (en) | 1994-08-26 |
| IL109749A true IL109749A (en) | 1999-03-12 |
Family
ID=10736089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10974994A IL109749A (en) | 1993-05-25 | 1994-05-24 | Rectal Pharmaceutical Preparations Containing 1, 2, 3, 9 - Tetrahydro - 9 - Methyl -3 -]) 2 - Methyl - H1 - Imidazole - 1 - Il (- Methyl - |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US5741806A (de) |
| EP (1) | EP0700290B1 (de) |
| JP (1) | JP2965703B2 (de) |
| KR (1) | KR100297212B1 (de) |
| CN (1) | CN1106194C (de) |
| AP (1) | AP544A (de) |
| AT (1) | ATE183643T1 (de) |
| AU (1) | AU680918B2 (de) |
| BE (1) | BE1007158A3 (de) |
| BR (1) | BR1100046A (de) |
| CA (1) | CA2162919C (de) |
| CO (1) | CO4230094A1 (de) |
| CY (1) | CY2411B1 (de) |
| CZ (1) | CZ291041B6 (de) |
| DE (1) | DE69420266T2 (de) |
| DK (1) | DK0700290T3 (de) |
| EC (1) | ECSP941088A (de) |
| ES (1) | ES2136198T3 (de) |
| FR (1) | FR2705569B1 (de) |
| GB (2) | GB9310756D0 (de) |
| GR (1) | GR3031669T3 (de) |
| HR (2) | HRP940315B1 (de) |
| HU (1) | HU227121B1 (de) |
| IE (1) | IE80632B1 (de) |
| IL (1) | IL109749A (de) |
| IS (1) | IS1868B (de) |
| IT (1) | IT1272990B (de) |
| MY (1) | MY111445A (de) |
| NO (1) | NO306448B1 (de) |
| NZ (1) | NZ267415A (de) |
| PE (1) | PE13395A1 (de) |
| PL (1) | PL175578B1 (de) |
| RU (1) | RU2132684C1 (de) |
| SA (1) | SA94150003B1 (de) |
| SG (1) | SG48119A1 (de) |
| SI (1) | SI0700290T1 (de) |
| WO (1) | WO1994027599A1 (de) |
| ZA (1) | ZA943593B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0102026A3 (en) | 1998-06-15 | 2002-12-28 | Sepracor Inc Marlborough | Use of optically pure (-) norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimis, and other disorders |
| EP1468685A3 (de) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Verwendung von optisch reines (+)-Norcisapride für die Behandlung von Apnea, Bulimia und andere Krankheiten |
| EP1464333A3 (de) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Verwendung von optisch reines (-) Norcisapride in der Behandlung von Apnea, Bulimia und andere Krankheiten |
| SK19052000A3 (sk) | 1998-06-15 | 2001-06-11 | Sepracor, Inc. | Použitie (+)norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (-)stereoizoméru na liečenie apnoe, bulímie a iných porúch |
| US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| CA2774959C (en) * | 2000-08-04 | 2016-05-31 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920003064B1 (ko) * | 1984-01-25 | 1992-04-13 | 글락소 그룹 리미티드 | 헤테로시클릭 화합물의 제조방법 |
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8627909D0 (en) * | 1986-11-21 | 1986-12-31 | Glaxo Group Ltd | Medicaments |
| GB8816187D0 (en) * | 1988-07-07 | 1988-08-10 | Glaxo Group Ltd | Medicaments |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
-
1993
- 1993-05-25 GB GB939310756A patent/GB9310756D0/en active Pending
-
1994
- 1994-05-17 SG SG1996007139A patent/SG48119A1/en unknown
- 1994-05-17 GB GB9409835A patent/GB2279008B/en not_active Expired - Lifetime
- 1994-05-17 EC EC1994001088A patent/ECSP941088A/es unknown
- 1994-05-19 IS IS4168A patent/IS1868B/is unknown
- 1994-05-20 MY MYPI94001305A patent/MY111445A/en unknown
- 1994-05-23 HR HR940315A patent/HRP940315B1/xx not_active IP Right Cessation
- 1994-05-23 IE IE940420A patent/IE80632B1/en not_active IP Right Cessation
- 1994-05-23 CO CO94021615A patent/CO4230094A1/es unknown
- 1994-05-23 PE PE1994242905A patent/PE13395A1/es not_active IP Right Cessation
- 1994-05-23 AP APAP/P/1994/000643A patent/AP544A/en active
- 1994-05-24 KR KR1019950705280A patent/KR100297212B1/ko not_active Expired - Lifetime
- 1994-05-24 WO PCT/EP1994/001652 patent/WO1994027599A1/en not_active Ceased
- 1994-05-24 US US08/537,950 patent/US5741806A/en not_active Expired - Lifetime
- 1994-05-24 FR FR9406252A patent/FR2705569B1/fr not_active Expired - Lifetime
- 1994-05-24 HU HU9503375A patent/HU227121B1/hu unknown
- 1994-05-24 CA CA002162919A patent/CA2162919C/en not_active Expired - Lifetime
- 1994-05-24 IL IL10974994A patent/IL109749A/en not_active IP Right Cessation
- 1994-05-24 RU RU95122578A patent/RU2132684C1/ru active
- 1994-05-24 IT ITRM940322A patent/IT1272990B/it active IP Right Grant
- 1994-05-24 BE BE9400528A patent/BE1007158A3/fr not_active IP Right Cessation
- 1994-05-24 EP EP94918355A patent/EP0700290B1/de not_active Expired - Lifetime
- 1994-05-24 NZ NZ267415A patent/NZ267415A/en not_active IP Right Cessation
- 1994-05-24 AT AT94918355T patent/ATE183643T1/de active
- 1994-05-24 JP JP7500204A patent/JP2965703B2/ja not_active Expired - Lifetime
- 1994-05-24 AU AU69709/94A patent/AU680918B2/en not_active Expired
- 1994-05-24 DE DE69420266T patent/DE69420266T2/de not_active Expired - Lifetime
- 1994-05-24 ES ES94918355T patent/ES2136198T3/es not_active Expired - Lifetime
- 1994-05-24 CN CN94192243A patent/CN1106194C/zh not_active Expired - Lifetime
- 1994-05-24 CZ CZ19953085A patent/CZ291041B6/cs not_active IP Right Cessation
- 1994-05-24 PL PL94311721A patent/PL175578B1/pl unknown
- 1994-05-24 DK DK94918355T patent/DK0700290T3/da active
- 1994-05-24 SI SI9430263T patent/SI0700290T1/xx unknown
- 1994-05-24 ZA ZA943593A patent/ZA943593B/xx unknown
- 1994-06-12 SA SA94150003A patent/SA94150003B1/ar unknown
-
1995
- 1995-11-24 NO NO954783A patent/NO306448B1/no not_active IP Right Cessation
-
1996
- 1996-09-19 BR BR1100046-5A patent/BR1100046A/pt active IP Right Grant
-
1997
- 1997-06-09 HR HR970315A patent/HRP970315A2/hr not_active Application Discontinuation
-
1999
- 1999-10-27 GR GR990402759T patent/GR3031669T3/el unknown
-
2000
- 2000-06-06 CY CY0000022A patent/CY2411B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2200046A (en) | Pharmaceutical compositions for gastric disorders | |
| US5705506A (en) | Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration | |
| AP544A (en) | Compositions for rectal administration | |
| AU626010B2 (en) | Medicaments | |
| EP0345931A1 (de) | Gewisse PAF-Antagonist/Antihistamin-Mischungen und Verfahren | |
| EP0567498A1 (de) | Arzneimittel, das granisetron und dexamethasone enthält | |
| JPH01250319A (ja) | 医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |